TNFRSF8 and Hodgkins lymphoma: BV is an antibody-drug conjugate (ADC) that targets CD30, a protein expressed on the surface of cancer cells in Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).